Pulsenmore

Pulsenmore Free Cash Flow

The Free Cash Flow (FCF) of Pulsenmore (PLSM.TA) as of Oct 31, 2026 is -33.01 M ILS. In the previous year, Free Cash Flow (FCF) was -34.22 M ILS — a change of -3.54% (higher).

Free Cash Flow

-33.01 MILS

YoY

-3.54%

Last updated:

Free Cash Flow (FCF) of Pulsenmore is 2025 -33.01 M ILS. Free Cash Flow (FCF) of Pulsenmore was 2024 -34.22 M ILS. It decreases by -3.54% higher compared to the previous year.

The Pulsenmore Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2019
-4.01 M ILS
Jan 1, 2020
-9.85 M ILS
Jan 1, 2021
-26.79 M ILS
Jan 1, 2022
-28.92 M ILS
Jan 1, 2023
-46.34 M ILS
Jan 1, 2024
-34.22 M ILS
Jan 1, 2025
-33.01 M ILS
The Pulsenmore Free Cash Flow history
YEARFree Cash FlowYoY
-33.01 MILS-3.54%
-34.22 MILS-26.15%
-46.34 MILS+60.23%
-28.92 MILS+7.97%
-26.79 MILS+171.80%
-9.85 MILS+145.57%
-4.01 MILS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pulsenmore Stock analysis

What does Pulsenmore do? Pulsenmore Ltd. generates revenue through the sale of its two miniaturized ultrasound systems, PulseNmore ES and PulseNmore FC, designed for home use in remote clinical diagnosis. The PulseNmore ES targets pregnant women requiring regular ultrasound monitoring, while PulseNmore FC caters to women undergoing in vitro fertilization needing follicle size assessments. Both systems integrate with smartphones, enabling patients to conduct tests at home and share results online with healthcare providers. The company also monetizes through software delivery for its devices, enhancing user experience and data management. The primary buyers of PulseNmore ES are pregnant women seeking convenient, clinic-free monitoring, and healthcare providers managing prenatal care remotely. PulseNmore FC is purchased by women undergoing in vitro fertilization, often through fertility clinics or medical centers that recommend the device. These segments value the convenience of home-based diagnostics and seamless telehealth integration without requiring in-person visits. Pulsenmore Ltd. focuses on global markets for its portable ultrasound solutions, serving patients in remote or underserved areas who benefit from telehealth-enabled diagnostics. The company’s products are positioned as cost-effective alternatives to traditional clinic visits, appealing to both end-users and healthcare institutions aiming to reduce operational costs while maintaining patient care quality. Pulsenmore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulsenmore stock

Free Cash Flow (FCF) of Pulsenmore is -33.01 M ILS in 2025.

Free Cash Flow (FCF) of Pulsenmore changed from -34.22 M ILS to -33.01 M ILS, representing a -3.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Pulsenmore since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Pulsenmore historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Pulsenmore

All Key Metrics — Pulsenmore